Advanced Filters
noise

Mild Cognitive Impairment Clinical Trials

A listing of Mild Cognitive Impairment medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 284 clinical trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not …

18 years of age All Phase 2/3
A Andras Perl, M.D., Ph.D.

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change …

18 years of age All Phase 2

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

18 - 65 years of age All Phase 1
S Sanbin Wang, MD

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)

14 - 75 years of age All Phase 1/2
Z Zhu chen, M.D.

Efficacy and Safety of HN2301 in Refractory Systemic Lupus Erythematosus (SLE)

This is an investigator-initiated trial designed to evaluate the safety, and efficacy of HN2301 in Relapsing and refractory systemic lupus erythematosus

18 - 69 years of age All Phase N/A
J Jinxia Zhao

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

The study is a single-arm, open-label clinical trial intended to recruit 6 refractory SLE subjects who meet the inclusion and exclusion criteria. The subjects will receive IM19 CAR-T cell infusion therapy at a dose of 1×10^6/kg or 1×10^8 CAR-T cells . The primary endpoint is to evaluate the improvement in …

18 - 65 years of age All Phase N/A
S Stephanie Dezzutti

UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

The goal of this clinical trial is to evaluate the safety and effectiveness of UC-MSCs in adults with systemic lupus erythematosus (SLE). The main questions this study aims to answer are: Can UC-MSCs improve kidney function and reduce SLE disease activity? Are UC-MSCs safe and well-tolerated in this patient population? …

18 - 75 years of age All Phase 1
L Lingli Dong, MD

Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed /refractory systemic lupus erythematosus (SLE).

18 years of age All Phase N/A
S S Fadilah Abdul Wahid, PhD

Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)

This pilot clinical study aims to evaluate the effectiveness of Chimeric Antigen Receptor (CAR) T-cell therapy in treating severe, refractory systemic lupus erythematosus (SLE), an autoimmune disease driven by autoreactive B-cells. Current treatments for severe SLE, including glucocorticoids, cytotoxic, and immunosuppressive drugs, have significant limitations. These treatments do not adequately …

18 - 65 years of age All Phase 1
N Nicolas Guillaume, Pr

HLA Antibodies in Systemic Lupus Erythematosus

Patients suffering from autoimmune diseases show false-positive results when anti-HLA antibodies are identified. This false positivity makes it difficult to obtain an organ transplant based on immunological compatibility (absence of anti-HLA antibodies directed against graft antigens). The objectives of this project are to study the prevalence of these false positivities …

18 years of age All Phase N/A

Simplify language using AI